Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Summary

The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.

Timeline

Start

2024-05-11

Primary completion

2027-07-11

Completion

2027-12-31

Drugs

Indications